HYPERINSULINEMIA AS A COMORBID CONDITION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Article Sidebar

PDF (Uzbek (latin))
Issue: Vol. 6 No. 2 : Eurasian Journal of Academic Research
Section: Articles
Published:
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Main Article Content

Ftiziatriya va pulmonologiya kafedrasi assistenti Toshkent davlat tibbiyot universiteti
info@in-academy.uz

Abstract:

Chronic obstructive pulmonary disease (COPD) is accompanied not only by impaired respiratory function, but also by systemic metabolic disorders. One of the main manifestations of metabolic syndrome is hyperinsulinemia - an increase in insulin levels in the blood, which can precede the development of insulin resistance (insulin resistance) and type 2 diabetes.

Keywords:

Article Details

How to Cite:

Fattaxov , R. (2026). HYPERINSULINEMIA AS A COMORBID CONDITION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). Eurasian Journal of Academic Research, 6(2), 66–70. Retrieved from https://www.in-academy.uz/index.php/ejar/article/view/74110

References:

Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–85.

Wouters E.F.M. Chronic obstructive pulmonary disease: systemic effects. Thorax. 2002;57(12):1067–70.

Park B.H., et al. COPD and metabolic syndrome: A nationwide survey in Korea. Int J Tuberc Lung Dis. 2012;16(5):694–700.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2023 Report.

Avdeev S.N., Ovcharenko S.I. Metabolic profile in COPD patients. Pulmonology. 2020;30(2):15–20.

American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–S154.

Cazzola M., et al. Comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(2):112–9.

Watz H., et al. Metabolic syndrome in COPD: systemic inflammation and physical inactivity. Chest. 2009;136(4):1039–46.

Yin H.L., et al. Prevalence of comorbidities in COPD patients: A meta-analysis. Medicine. 2017;96(19):e6836.

Samuleeva Yu.V., et al. [Метаболические нарушения у больных ХОБЛ]. Пульмонология. 2014;5:32–38.

Catana O.M., Nemes A.F., Cioboata R., et al. Leptin and Insulin in COPD: Unveiling the Metabolic-Inflammatory Axis—A Narrative Review. J Clin Med. 2025;14:2611.